NCT06322056View on ClinicalTrials.gov

Exploring Approaches With Lower Targets of Blood Pressure and Lipid for Improving Renal Outcome in Advanced Chronic Kidney Disease

NARecruitingINTERVENTIONAL
Enrollment

642

Participants

Timeline

Start Date

May 13, 2024

Primary Completion Date

May 31, 2029

Study Completion Date

August 31, 2029

Conditions
Chronic Kidney DiseasesHypertensionDyslipidemias
Interventions
DRUG

Intensive control of SBP and intensive control of LDL-C

Eligible participants would be assigned to a SBP target of less than 120 mmHg and a LDL-C target of less than 70 mg/dL.

DRUG

Intensive control of SBP and standard control of LDL-C

Eligible participants would be assigned to a SBP target of less than 120 mmHg and a LDL-C target of less than 100 mg/dL.

DRUG

Standard control of SBP and intensive control of LDL-C

Eligible participants would be assigned to a SBP target of less than 140 mmHg and a LDL-C target of less than 70 mg/dL.

DRUG

Standard control of SBP and standard control of LDL-C

Eligible participants would be assigned to a SBP target of less than 140 mmHg and a LDL-C target of less than 100 mg/dL.

Trial Locations (1)

03722

RECRUITING

Severance Hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER